I don't think people have really modeled in the generics acquisitions yet. The generics acquisition isn't something that has been seen positively yet.

European pharmaceuticals have outperformed quite considerably over the last year or so. Fundamentally, they should continue doing better in 2006.

Their products are quite unique. The figures were strong.

As other players have moved out of the vaccines business, it has become more interesting for others to go in. The manufacturers that are left gain a lot of pricing power, and interest has also risen in the face of pandemic risks.

The worst is over, ... People are returning to their normal lives.

He's got Venezuela people crazy,